PReS-FINAL-2274: Antiadalimumab antibodies in pediatric rheumatology patients. A pilot experience

Detalles Bibliográficos
Autores principales: Murias Loza, S, Alcobendas Rueda, RM, Remesal Camba, A, Pascual Salcedo, D, Peralta, J, Merino Muñoz, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4044380/
http://dx.doi.org/10.1186/1546-0096-11-S2-P264
_version_ 1782319136687259648
author Murias Loza, S
Alcobendas Rueda, RM
Remesal Camba, A
Pascual Salcedo, D
Peralta, J
Merino Muñoz, R
author_facet Murias Loza, S
Alcobendas Rueda, RM
Remesal Camba, A
Pascual Salcedo, D
Peralta, J
Merino Muñoz, R
author_sort Murias Loza, S
collection PubMed
description
format Online
Article
Text
id pubmed-4044380
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40443802014-06-19 PReS-FINAL-2274: Antiadalimumab antibodies in pediatric rheumatology patients. A pilot experience Murias Loza, S Alcobendas Rueda, RM Remesal Camba, A Pascual Salcedo, D Peralta, J Merino Muñoz, R Pediatr Rheumatol Online J Poster Presentation BioMed Central 2013-12-05 /pmc/articles/PMC4044380/ http://dx.doi.org/10.1186/1546-0096-11-S2-P264 Text en Copyright © 2013 Murias Loza et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Poster Presentation
Murias Loza, S
Alcobendas Rueda, RM
Remesal Camba, A
Pascual Salcedo, D
Peralta, J
Merino Muñoz, R
PReS-FINAL-2274: Antiadalimumab antibodies in pediatric rheumatology patients. A pilot experience
title PReS-FINAL-2274: Antiadalimumab antibodies in pediatric rheumatology patients. A pilot experience
title_full PReS-FINAL-2274: Antiadalimumab antibodies in pediatric rheumatology patients. A pilot experience
title_fullStr PReS-FINAL-2274: Antiadalimumab antibodies in pediatric rheumatology patients. A pilot experience
title_full_unstemmed PReS-FINAL-2274: Antiadalimumab antibodies in pediatric rheumatology patients. A pilot experience
title_short PReS-FINAL-2274: Antiadalimumab antibodies in pediatric rheumatology patients. A pilot experience
title_sort pres-final-2274: antiadalimumab antibodies in pediatric rheumatology patients. a pilot experience
topic Poster Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4044380/
http://dx.doi.org/10.1186/1546-0096-11-S2-P264
work_keys_str_mv AT muriaslozas presfinal2274antiadalimumabantibodiesinpediatricrheumatologypatientsapilotexperience
AT alcobendasruedarm presfinal2274antiadalimumabantibodiesinpediatricrheumatologypatientsapilotexperience
AT remesalcambaa presfinal2274antiadalimumabantibodiesinpediatricrheumatologypatientsapilotexperience
AT pascualsalcedod presfinal2274antiadalimumabantibodiesinpediatricrheumatologypatientsapilotexperience
AT peraltaj presfinal2274antiadalimumabantibodiesinpediatricrheumatologypatientsapilotexperience
AT merinomunozr presfinal2274antiadalimumabantibodiesinpediatricrheumatologypatientsapilotexperience

Ejemplares similares